Literature DB >> 10816447

Extending the CD4(+) T-cell epitope specificity of the Th1 immune response to an antigen using a Salmonella enterica serovar typhimurium delivery vehicle.

R Lo-Man1, J P Langeveld, E Dériaud, M Jehanno, M Rojas, J M Clément, R H Meloen, M Hofnung, C Leclerc.   

Abstract

We analyzed the CD4 T-cell immunodominance of the response to a model antigen (Ag), MalE, when delivered by an attenuated strain of Salmonella enterica serovar Typhimurium (SL3261*pMalE). Compared to purified MalE Ag administered with adjuvant, the mapping of the peptide-specific proliferative responses showed qualitative differences when we used the Salmonella vehicle. We observed the disappearance of one out of eight MalE peptides' T-cell reactivity upon SL3261*pMalE immunization, but this phenomenon was probably due to a low level of T-cell priming, since it could be overcome by further immunization. The most striking effect of SL3261*pMalE administration was the activation and stimulation of new MalE peptide-specific T-cell responses that were silent after administration of purified Ag with adjuvant. Ag presentation assays performed with MalE-specific T-cell hybridomas showed that infection of Ag-presenting cells by this intracellular attenuated bacterium did not affect the processing and presentation of the different MalE peptides by major histocompatibility complex (MHC) class II molecules and therefore did not account for immunodominance modulation. Thus, immunodominance of the T-cell response to microorganisms is governed not only by the frequency of the available T-cell repertoire or the processing steps in Ag-presenting cells that lead to MHC presentation but also by other parameters probably related to the infectious process and to the bacterial products. Our results indicate that, upon infection by a microorganism, the specificity of the T-cell response induced against its Ags can be much more effective than with purified Ags and that it cannot completely be mimicked by purified Ags administered with adjuvant.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10816447      PMCID: PMC97535          DOI: 10.1128/IAI.68.6.3079-3089.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  61 in total

1.  Acidification of phagosomes containing Salmonella typhimurium in murine macrophages.

Authors:  M Rathman; M D Sjaastad; S Falkow
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Differential regulation of Ia expression and antigen presentation by listeriolysin-producing versus non-producing strains of Listeria monocytogenes.

Authors:  M A Vazquez; S C Sicher; M L Proctor; J C Crowley; C Y Lu
Journal:  J Leukoc Biol       Date:  1996-05       Impact factor: 4.962

3.  Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway.

Authors:  K L Rock; K Clark
Journal:  J Immunol       Date:  1996-05-15       Impact factor: 5.422

Review 4.  HLA-DM: an in vivo facilitator of MHC class II peptide loading.

Authors:  P A Roche
Journal:  Immunity       Date:  1995-09       Impact factor: 31.745

5.  Antiviral immunity induced by recombinant nucleoprotein of influenza A virus. I. Characteristics and cross-reactivity of T cell responses.

Authors:  J P Tite; S M Russell; G Dougan; D O'Callaghan; I Jones; G Brownlee; F Y Liew
Journal:  J Immunol       Date:  1988-12-01       Impact factor: 5.422

6.  Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis.

Authors:  J Hess; I Gentschev; D Miko; M Welzel; C Ladel; W Goebel; S H Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

7.  In vivo priming of T cells against cryptic determinants by dendritic cells exposed to interleukin 6 and native antigen.

Authors:  H Drakesmith; D O'Neil; S C Schneider; M Binks; P Medd; E Sercarz; P Beverley; B Chain
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

8.  Differential production of interleukin-12 mRNA by murine macrophages in response to viable or killed Salmonella spp.

Authors:  C Chong; K L Bost; J D Clements
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

9.  Dendritic cells but not B cells present antigenic complexes to class II-restricted T cells after administration of protein in adjuvant.

Authors:  J C Guéry; F Ria; L Adorini
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

10.  Mechanisms influencing the immunodominance of T cell determinants.

Authors:  L Adorini; E Appella; G Doria; Z A Nagy
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

View more
  11 in total

1.  Delivery of a MalE CD4(+)-T-cell epitope into the major histocompatibility complex class II antigen presentation pathway by Bordetella pertussis adenylate cyclase.

Authors:  Jiina Loucká; Géraldine Schlecht; Jana Vodolánová; Claude Leclerc; Peter Sebo
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

Review 2.  Regulation of CD4 T-cell receptor diversity by vaccine adjuvants.

Authors:  Christina K Baumgartner; Laurent P Malherbe
Journal:  Immunology       Date:  2010-03-17       Impact factor: 7.397

3.  A vaccine candidate for post-weaning diarrhea in swine constructed with a live attenuated Salmonella delivering Escherichia coli K88ab, K88ac, FedA, and FedF fimbrial antigens and its immune responses in a murine model.

Authors:  Jin Hur; Barry D Stein; John Hwa Lee
Journal:  Can J Vet Res       Date:  2012-07       Impact factor: 1.310

4.  Tn glycosylation of the MUC6 protein modulates its immunogenicity and promotes the induction of Th17-biased T cell responses.

Authors:  Teresa Freire; Richard Lo-Man; Sylvie Bay; Claude Leclerc
Journal:  J Biol Chem       Date:  2010-12-30       Impact factor: 5.157

5.  Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine.

Authors:  Gregory P Priebe; Mary M Brinig; Kazue Hatano; Martha Grout; Fadie T Coleman; Gerald B Pier; Joanna B Goldberg
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

6.  Fine-tuning synthesis of Yersinia pestis LcrV from runaway-like replication balanced-lethal plasmid in a Salmonella enterica serovar typhimurium vaccine induces protection against a lethal Y. pestis challenge in mice.

Authors:  Ascención Torres-Escobar; María Dolores Juárez-Rodríguez; Bronwyn M Gunn; Christine G Branger; Steven A Tinge; Roy Curtiss
Journal:  Infect Immun       Date:  2010-03-22       Impact factor: 3.441

7.  Delivery of woodchuck hepatitis virus-like particle presented influenza M2e by recombinant attenuated Salmonella displaying a delayed lysis phenotype.

Authors:  Keith Ameiss; Shamaila Ashraf; Wei Kong; Andrew Pekosz; Wai-Hong Wu; David Milich; Jean-Noel Billaud; Roy Curtiss
Journal:  Vaccine       Date:  2010-08-05       Impact factor: 3.641

8.  Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccine.

Authors:  Ho Young Kang; Jay Srinivasan; Roy Curtiss
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

9.  Delivery of the immunosuppressive antigen Salp15 to antigen-presenting cells by Salmonella enterica serovar Typhimurium aroA mutants.

Authors:  Amir-Reza T Motameni; Ignacio J Juncadella; Shobana K Ananthanarayanan; Michael N Hedrick; Yvette Huet-Hudson; Juan Anguita
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

10.  An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis.

Authors:  Laleh Majlessi; Marcela Simsova; Zdenka Jarvis; Priscille Brodin; Marie-Jésus Rojas; Cécile Bauche; Clémence Nouzé; Daniel Ladant; Stewart T Cole; Peter Sebo; Claude Leclerc
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.